Law scholar Jonathan Turley took on Fox News’s Chris Wallace regarding Judge Amy Coney Barrett’s confirmation hearings for the Supreme Court and the Affordable Care Act.
“You need, truly, waders to get through the rising hypocrisy from both parties. That’s nothing new. Both parties are adopting the opposite views that they had in 2016. Although I’m not too sure the Democrats would be doing anything different if they were given this vacancy and this opportunity. But I want … Chris Wallace raises some good points. The lower court did strike down the ACA, but there … does not appear to be a majority of votes from our count of overturning the entire Act. In fact, the betting money is that conservatives might join liberals,” Turley said on Monday on Fox News.
Wallace interjected, “Jonathan, if I may, you know, the point I’m simply making
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep 30, 2020–
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two poster presentations as part of the World Muscle Society (WMS) 2020 Virtual Congress. The SRK-015 clinical development poster will showcase previously presented data from the Phase 1 healthy volunteer trial, as well as baseline characteristics and demographics from the TOPAZ Phase 2 proof-of-concept trial evaluating SRK-015 for the treatment of patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA). The second poster shares data on the pharmacologic effects of SRK-015 in patients with SMA, healthy volunteers, and across animal species.
Details for the two virtual posters at the WMS meeting are as follows:
- Title: Clinical Development of SRK-015, a Fully Human Anti-proMyostatin Monoclonal Antibody, for the Treatment of Later-Onset Spinal Muscular Atrophy
- Title: Myostatin